ROYCE & ASSOCIATES LP - PARATEK PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
ROYCE & ASSOCIATES LP ownership history of PARATEK PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2019$1,274,000
+34.4%
294,800
+24.0%
0.01%
+33.3%
Q2 2019$948,000
-44.3%
237,700
-25.2%
0.01%
-35.7%
Q1 2019$1,703,000
+4.5%
317,7000.0%0.01%
-6.7%
Q4 2018$1,630,000
-57.4%
317,700
-19.4%
0.02%
-42.3%
Q3 2018$3,825,000
-9.2%
394,369
-4.5%
0.03%
-10.3%
Q2 2018$4,211,000
-16.9%
412,869
+6.0%
0.03%
-17.1%
Q1 2018$5,066,000
-21.4%
389,669
+8.2%
0.04%
-18.6%
Q4 2017$6,449,000
-12.4%
360,269
+22.9%
0.04%
-12.2%
Q3 2017$7,359,000
+7.9%
293,200
+3.6%
0.05%
+8.9%
Q2 2017$6,818,000
+167.1%
282,900
+113.3%
0.04%
+164.7%
Q1 2017$2,553,000132,6000.02%
Other shareholders
PARATEK PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
AIGH Capital Management LLC 2,339,107$10,502,0003.20%
Telemetry Investments, L.L.C. 262,279$1,178,0001.52%
Bruce & Co., Inc. 1,443,312$6,480,0001.30%
Omega Fund Management, LLC 1,971,241$8,851,0001.25%
Worth Venture Partners, LLC 556,832$2,500,0001.24%
Abingworth LLP 1,041,131$4,654,0001.13%
1492 Capital Management LLC 491,033$2,205,0001.09%
CM Management, LLC 300,000$1,347,0001.02%
Trellus Management Company, LLC 295,000$1,325,0000.88%
GENERAL AMERICAN INVESTORS CO INC 1,306,919$5,868,0000.46%
View complete list of PARATEK PHARMACEUTICALS INC shareholders